Chembio Diagnostics — Investor Presentation (August 2018)
21 slides from Chembio Diagnostics's investor presentation, Aug 8, 2018
Slide 1: Chembio Diagnostic Systems, Inc.
@CHEMBIO DIAGNOSTIC SYSTEMS, INC,
Slide 2: Corporate Presentation August 8, 2018
© 2018 Chembio. All Rights Reserved. | # Corporate Presentation August 8, 2018 © 2018 Chembio. All Rights Reserved. Page 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such st
Slide 4: Our Vision and Mission
Our VisionTo reduce the incidence of disease globallyOur MissionTo develop and commercialize rapid, easy-to-use, and reliable point-of-care tests that improve diagnosis and monitoring of disease © 2018 Chembio. All Rights Reserved. Page 3
Slide 5: Patented DPP Technology Platform
© 2018 Chembio. All Rights Reserved. | # Patented DPP® Technology Platform 99.8%Sensitivity1100% Specificity1 Offers uniqueness and broad global market application 1Based on fingerstick whole blood samples: DPP HIV 1/2 Assay Easy to useFingerstick blood / oral fluidResults in 10-20 minutesHighly sen
Slide 6: Strategic Focus
EXPANDING…Our core sexually transmitted disease (STD) businessBUILDING…A broad tropical and fever disease portfolioLEVERAGING…Our DPP® technology and scientific expertise via collaborationsPREPARING…For additional growth with enhanced manufacturing capability Strategic Focus Executing on our key bui
Slide 7: Expanding our Core STD Business
Expanding our Core STD Business Multiple organic growth drivers are moving the business BROADEN - expand product offering © 2018 Chembio. All Rights Reserved. Page 6
Slide 8: Sexually Transmitted Disease Market
Sexually Transmitted Disease Market HIV and Syphilis affect ~50 million globally IMPORTANT GEOGRAPHIESUnited States: FDA approved, CLIA WaivedAfrica: WHO prequalifiedEurope: CE markedBrazil: ANVISA approvedMexico: COFEPRIS approvedMalaysia: MDA approved © 2018 Chembio. All Rights Reserved. Page 7
Slide 9: Sexually Transmitted Disease Products
KEY ADVANTAGESSmall sample size2.5 – 15μL fingerstick blood sample Fast results15-20 minute test timeReliable performanceSensitive and SpecificMultiplexing capabilitiesDPP® HIV-SyphilisDPP® Syphilis Screen & Confirm SURE CHECK® HIV 1/2 Test STAT-PAK® HIV 1/2 Test SURE CHECK® HIV Self Test DPP® HIV-S
Slide 10: DPP HIV-Syphilis Test
Global community committed to eliminating mother-to-child transmission Addressing HIV-Syphilis Co-infection United StatesSubmitted U.S. FDA application Q1 2018Expect response by Q3 2018International Regulatory ApprovalsANVISA approved (Brazil)COFEPRIS approved (Mexico)USAID approvedCE markedOther ©
Slide 11: Building Tropical & Fever Disease Portfolio
Building Tropical & Fever Disease Portfolio DPP® Malaria DPP® Dengue DPP® Zika DPP® Chikungunya DPP® Ebola DPP® Typhoid DPP® Fever Panel(Africa) DPP® Malaria-Ebola DPP® Dengue-Zika-Chikungunya DPP® Fever Panel(Asia) Single Tests Multiplex Tests Key advantages include sensitivity, specificity and mul
Slide 12: Tropical and Fever Disease Market
Opportunities in Established MarketsMalaria: 216M annual infectionsDengue: 390M annual infectionsEmerging Markets ZikaChikungunyaEbolaLassaMarburgLeptospirosisBurkholderiaRickettsia Tropical and Fever Disease Market Established markets and channels present significant opportunity © 2018 Chembio. All
Slide 13: Tropical and Fever Disease R&D Funding
Tropical and Fever Disease R&D funding from World-Leading Organizations: $7.3MM (’15-’17) DPP® Malaria DPP® Dengue DPP® Zika DPP® Dengue/Zika/Chikungunya DPP® Fever Panel - Africa DPP® Fever Panel - Asia DPP® Ebola DPP® Malaria/Ebola © 2018 Chembio. All Rights Reserved. Page 12
Slide 14: Technology Collaborations: Why Global Leaders Choose Chembio
Technology Collaborations Why are global leaders choosing Chembio to solve their challenges? © 2018 Chembio. All Rights Reserved. Page 13 Deep scientific expertise with a proven technology platformSensitive and specificMultiplexing capabilitiesQuantitative resultsSuccessful track record developing D
Slide 15: Technology Collaborations: Ongoing Collaborations
Technology Collaborations Ongoing collaborations provide significant growth potential DPP® Concussion DPP® Bovine Tuberculosis DPP® Cancer (specific form) DPP® “Undisclosed Biomarker” Point-of-care infectious disease portfolio Perseus Science Group LLC Undisclosed Partner © 2018 Chembio. All Rights
Slide 16: Technology Collaboration Opportunities
Technology Collaborations What opportunities do our technology collaborations provide? © 2018 Chembio. All Rights Reserved. Page 15 Expansion into new marketsCancer DiagnosticsConcussion / Traumatic Brain InjuryVeterinaryBroadening application from POC diagnostics to companion diagnosticsDrugsVaccin
Slide 17: Preparing For Additional Growth
Preparing For Additional Growth Product, People, Process Expanding the product portfolio (STD, Tropical & Fever, Collaborations)Strengthening the talent (Leadership, Board, Organization)Expanding manufacturing capacity (U.S. and Malaysia) © 2018 Chembio. All Rights Reserved. Page 16
Slide 18: Financial Highlights
© 2018 Chembio. All Rights Reserved. | # Revenue (millions) As of 6/30/2018$9.5M cash and equivalents; $16.9M net working capital Q3 2016 Q3 2017 Q4 2016 Q4 2017 Q1 2017 Q1 2018 Q2 2017 Q2 2018 Financial Highlights Revenue Growth 63% LTM: $18.4M (Q2 ’17) to $30.0M (Q2 ’18) © 2018 Chembio. All Rights
Slide 19: 2018 Milestones, Goals and Next Steps
2018 Milestones, Goals and Next Steps Complete DPP® Malaria Assay development file registrationsComplete DPP® biomarker (AstraZeneca) development file registrationsSubmit DPP® Zika 510(k) with U.S. FDA launch in the U.S. marketFile DPP® Dengue registrations launch in APAC and LATAM marketsCo
Slide 20: Investment Highlights
Investment Highlights Investment Highlights Superior DPP® technology platform with broad applicationGrowing pipeline of products and markets Nimble global organization prepared to scale operationally © 2018 Chembio. All Rights Reserved. Page 19
Slide 21: © 2018 Chembio. All Rights Reserved. Page 20
© 2018 Chembio. All Rights Reserved. Page 20
Chembio Diagnostics — Investor Presentation (August 2018) on 6ix